| Theme | Intestinal mucosal immunology update for clinician | |
|---|---|---|
| Title | Treatment of inflammatory bowel disease with probiotics | |
| Publish Date | 2011/09 | |
| Author | Keiichi Mitsuyama | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Satoshi Matsumoto | Yakult Central Institute for Microbiological Research |
| Author | Hiroshi Yamasaki | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Kotaro Kuwaki | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Hidetoshi Takedatsu | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Shinichiro Yoshioka | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Koji Nagayama | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Teppei Kobayashi | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Osamu Tsuruta | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Michio Sata | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| [ Summary ] | Although the cause of inflammatory bowel disease (IBD) remains only partially understood, the current model favors a dysregulated immune system which is triggered by an environmental factor in a genetically-susceptible host. There is evidence that intestinal microflora play a significant role as environmental triggers. Identification of the link between intestinal microflora and IBD has led to a number of studies being conducted which have investigated the therapeutic potential of bacterial modification of the luminal environment using probiotics. Altering the composition of intestinal microflora through introduction of probiotics may improve clinical outcomes for patients with IBD. This review summarizes current clinical knowledge concerning in vitro experiments, in vivo animal studies and human clinical trials employing probiotics. | |